Spoken Alpha
SCYNEXIS INC
SCYNEXIS, Inc. develops antifungal medications to treat drug-resistant fungal infections. The company's lead product, ibrexafungerp (BREXAFEMME), was FDA-approved for vulvovaginal candidiasis and is licensed to GSK.
SCYNEXIS INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $44.1M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
5 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SCYX.
$ curl https://api.spokenalpha.com/v1/companies/SCYXFAQ
Spoken Alpha indexes SCYX's earnings call transcripts at https://spokenalpha.com/companies/SCYX. Each call links to attributed speakers and parsed analyst Q&A. SCYNEXIS INC's own investor relations page is at https://ir.scynexis.com/.
SCYNEXIS INC (SCYX) held its most recent earnings call on 2022-11-09, covering fiscal Q3 2022.
SCYNEXIS INC (SCYX) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.40 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-09 | $-0.32 | $-0.40 | +20.0% | $235.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-3.36 | $-0.99 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-04 | $2.00 | $1.01 | +97.4% | $18.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.17 | $-0.21 | +19.1% | $334.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-1.12 | $-1.52 | +26.3% | $1.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.17 | $-0.23 | +26.1% | $257.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-11 | $-0.09 | $-0.22 | +59.1% | $977.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.48 | $-0.78 | +38.5% | $660.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-2.40 | $-1.62 | -48.1% | $736.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $0.08 | $-1.55 | +100.0% | $1.4M | — | — | EODHD |
| Q4 FY2023 | 2024-02-06 | $-0.39 | $-0.20 | -95.0% | $5.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.32 | $-1.17 | +72.7% | $1.8M | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $19.68 | $11.62 | +69.4% | $131.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.71 | $-0.28 | -100.0% | $1.1M | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-2.32 | $-3.25 | +28.6% | $1.5M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-4.96 | $-3.94 | -25.9% | $1.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-2.48 | $-4.72 | +47.5% | $1.3M | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-1.36 | $-6.20 | +78.1% | $687.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-28 | $-1.05 | $-0.77 | -36.4% | $597.0K | — | — | EODHD |
Source: EODHD. SCYX reported actuals as published; sparse fields render as —.